An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

Abstract

TMC 125, a next generation NNRTI, is well tolerated and demonstrates significant and rapid antiviral activity in patients with high levels of phenotypic NNRTI resistance to current NNRTI.